News – Page 1066 – Endpoints News

J&J antes up on a $1B gamble that Theravance has the next blockbuster JAK for Crohn’s, ulcerative colitis

8 years ago

Secret meetings, mergers and a board putsch: Arcturus founder/CEO claims 4 board members conspired on his ouster

8 years ago

Taking on lousy side effects of existing meds, NEA-backed Xoc tackles Parkinson’s/migraines with $30M Series A

8 years ago

Nessan Bermingham returns to VC life; Sanofi's generics unit gets two industry bidders in EMS and Torrent Pharma

8 years ago

Array MEK/BRAF combo beats out Roche rival in PhIII melanoma OS showdown

8 years ago

Eyeing a blockbuster migraine market, Allergan takes an inside track on acute cases with positive PhIII

8 years ago

Zogenix wins inside track at FDA with childhood epilepsy ‘breakthrough’

8 years ago

The Endpoints 100: Biotech execs stampede into 2018 with a cheer for the FDA and bullish feelings on public markets, ...

8 years ago

Looking to grow blockbuster Pomalyst franchise, Celgene declares a win for multiple myeloma triplet in pivotal PhIII

8 years ago

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data

8 years ago

Pfizer vs J&J: Researchers are duking it out for the championship title in nonmetastatic prostate cancer

8 years ago

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet

8 years ago

Allergan taps Catalent's Matthew Walsh as CFO; ReViral meets endpoints in PhIIa RSV trial

8 years ago

Stock plummets at EyeGate following Phase IIb flop for cataract surgery

8 years ago

As controversy over childhood deaths simmers in the Philippines, Sanofi balks at a Dengvaxia reimbursement

8 years ago

Skeptics pounce after Bristol-Myers scores an early hit on Opdivo-Yervoy combo for lung cancer

8 years ago

Anatomy of a $9B buyout: Celgene’s quick turn from Juno’s close collaborator to new owner

8 years ago

Hans Bishop gets a $287M payday as Juno execs see windfall fortunes — with a $922M payoff for Arch

8 years ago

Slammed by a trial hold, Intarcia terminates studies and axes staff in wake of an FDA rejection

8 years ago

Buyout buzz hits fever pitch on report that Nektar is ‘exploring options’

8 years ago

Kenji Yasukawa takes the reins at Astellas; Voyager hunts for new CEO as Steven Paul goes back to research

8 years ago

Billion-dollar biosim maker mulls $500M Hong Kong IPO

8 years ago

Voyager co-founder Steven Paul steps down from CEO seat; Alnylam enters final stretch at the FDA with patisiran

8 years ago

RNA biotech Arcturus boots CEO Joseph Payne

8 years ago

First page Previous page 1063 1064 106510661067 1068 1069 Next page Last page